
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is viewed favorably because its lead Huntington’s disease program, AMT-130, has shown meaningful slowing across multiple endpoints, with statistically significant benefits on TFC in the 3-year data and supportive signals despite the mixed 4-year read. The fundamental thesis is strengthened by a notably more constructive FDA backdrop, as the agency now appears open to a BLA based on the 3-year data and a confirmatory study using standard of care rather than sham surgery, which materially lowers regulatory and operational risk. Support also comes from a proven gene-therapy execution record, a first-in-class Hemophilia B asset with 37% FIX activity versus about 20% for PFE, and promising pipeline progress in mTLE and Fabry.
Bears say
uniQure is facing a highly uncertain investment case because its value depends on successful execution across multiple risky programs while also navigating commercial launch delays for HEMGENIX. Clinical setbacks in Huntington’s disease, SOD1 ALS, and temporal lobe epilepsy, along with regulatory uncertainty, intellectual property risk, and the possibility of safety signals or failure to show sustained efficacy, could materially undermine the pipeline. Competitive pressure from PFE, IONS, and WVE, plus long-term pricing pressure on HEMGENIX, further weakens the fundamental outlook and raises the risk that future commercialization and returns disappoint.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About uniQure (QURE) Forecast
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares